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Determination of Human Body Burden
Baseline Data of Platinum through Autopsy
TissueAnalysis
by F. Vandiver P. Duffield,* Anna Yoakum,t Joseph Bumgarner,* and John
Moran*
Results ofanalysis for platinum in 97 autopsy sets are presented. Analysis was performed by a
specially developed emission spectrochemical method. Almost half of the individuals studied
were found to have detectable platinum in one or more tissue samples. Platinum was found to be
deposited in 13 of 21 tissue types investigated. Surprisingly high values were observed in sub-
cutaneous fat, previously not considered to be a target site for platinum deposition. These data
will serve as ahumantissueplatinum burden baselineinEPA's Catalyst Research Program.
Introduction
This report presents baseline data on various
human tissue burdens ofplatinum. The work was
done as part of the Environmental Protection
Agency's catalyst research program, which in-
cludes some 18 tasks on health effects of the no-
ble metals platinum and palladium. The impetus
for the program was Title II provisions of the
Clean Air Act of 1970, as amended, which re-
quires reduction of CO, HC, and NO, emissions
from light-duty motor vehicles. The automobile
industry's response was the introduction of noble
metal catalysts to reduce the regulated emis-
sions. In California all American-made 1975
model automobiles would be equipped with noble
metal catalytic converters; in the other 49 states,
some 70% would be so equipped. The number of
catalyst-equipped vehicles was estimated to in-
crease rapidly over the next ten years, replacing
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the pre-1975 noncatalyst vehicle population at a
rate of about 10%/yr (1). Since the employment
of the. noble metal catalytic converter repre-
sented introduction of a new environmental con-
taminant, it was imperative that a rather broad
Table 1. Areas of study of noble metal health effects in EPA
catalyst research program.
Emission characterization (Exhaust)
Measurementmethodology development
Exhaust
Ambientair, water, soil
Animaland humantissue,feces, urine
Standardreference material development
Bioenvironmental impact
Methylation chemistry
Population exposure studies
Toxicology
Carcinogenicity
Mutagenicity
Cytogenicity
Inhalation toxicology
Sensitization (allergic
response)
Irritation
Immunology
Body burden tissueanalysis
Healtheffects assessment
June 1976 131integrated information base be developed very
quickly. A listing of areas of study undertaken by
EPA is presented in Table 1.
Objective
Determination of human tissue burdens of
platinum prior to widespread use of the catalytic
converter emerged as a key task among the pro-
gram's areas of study. Future evaluations of no-
ble metal health effects would depend in part
upon the ability of researchers to compare base-
line (precatalyst) burdens with later human
burdens.
Approach
During the winter of 1974-75, autopsy
specimens were gathered through the Environ-
mental Protection Agency's Community Health
Environmental Surveillance System (CHESS)
(2). Up to 21 tissue samples were taken from each
of 97 autopsied individuals, of whom 95 had resid-
ed in southern California (Los Angeles area).
Tissue sample types analyzed (total 21) were
prostate or uterus, thyroid, kidney, brain, gonad,
adrenals, pancreas, heart (left ventricle), lung,
liver, aorta (descending), muscle (psoas), subcu-
taneous fat, vertebrae (lumbar), fifth rib, femur,
scalp hair, axillary hair, pubic hair, clavicle, and
spleen.
Samples were frozen and shipped as soon as
possible to Stewart Laboratories for analysis.
The method for analysis had been developed by
Stewart Laboratories and utilized an emission
spectrochemical method for the determination of
trace quantities ofplatinum, lead, and manganese
in biological tissue. The analytical technique
employed in the study-an emission spectrochem-
ical method utilizing total energy burns in an
argon-oxygen atmosphere-has been described
previously (3). Although the method does not
possess sufficient sensitivity to afford a total
evaluation of residual baseline platinum concen-
trations in autopsy tissues, a detection limit of 10
parts per billion (ppb) can be obtained for a 1-g
wet tissue sample. The analytical technique rep-
resents a method whose applicability is not de-
pendent on the effectiveness of the sample prep-
aration procedure to prepare a solution which is
totally applicable to the potential complexities of
platinum compounds which may be present. Total
platinum in the sample is analyzed regardless of
its chemical state since the method is limited only
by its inherent sensitivity. As in all autopsy sam-
ple studies, sample size varied greatly.
In addition to the tissue analyses, the following
data were available through the CHESS study for
92 of the 97 autopsy sets studied: age, race, sex,
occupation, and cause of death. Clinical summa-
ries, where available, were studied; there were
no indications that platinum tumor suppressant
therapy might have been a source of platinum ex-
posure. Similarly, occupational information
available did not indicate opportunity for occupa-
tional exposure to platinum.
Results
Of a total of 1313 samples obtained from the 97
individuals and analyzed for platinum, 62 con-
tained detectable platinum concentrations. Ofthe
97 autopsied individuals, 45 had detectable con-
centrations of platinum in one or more tissue
samples. Thus, though platinum was detected in
only 5%of the samples analyzed, 46% of the in-
dividuals had detectable platinum in at least one
type of tissue (see Table 2). The range of plat-
inum concentrations detected was 0.003 to 1.46
,ug/g (wet tissue); the mean value of detected
platinum was 0.16 Ag/g, and the median value of
detected platinum was 0.067 Ag/g.
Table 2. Individuals with detectable platinum concentrations.
Number %
Individuals in study 97 100
Individuals with Pt in one or more detected
tissue 45 46
Individuals with Pt in one tissue (27) (28)
Individuals withPt in twotissues (18) (18)
Individuals without detected Pt 52 54
The individual's age, sex, occupation, or major
disease process cited as cause ofdeath did not ap-
pear to be significant to platinum tissue burden.
Age and sex characteristics of those individuals
in whom platinum was detected in the tissues are
presented in Table 3.
Table 3. Age and sex characterization ofindividuals showingdetectable platinum concentrations.
Average Male Female Unknown
age, yr No. % No. 0/0 No. %
Total individuals instudy 61.5 39 40 52 54 6 6
Individuals with detected Pt 60.5 17 38 26 58 2 4
Individuals with Pt detected in twotissuesamples 57.3 7 38 11 62 0 0
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FIGURE 1. Distribution of Pt detected in tissue by age group (15-90) and sex. The points (-) denote detectible Pt concentration.
The apparent "target" sites for platinum
deposition in the individuals studied, i.e. tissues
in which the highest concentrations of platinum
were found were, in descending order: sub-
cutaneous fat, kidney, pancreas, and liver (Table
4).
Tissue deposition of detected platinum concen-
trations were plotted according to age and sex.
Distribution profile followed the age and sex pro-
file of the group fairly closely, so that there ap-
pears to be no particular age or sex bias for
platinum concentration (Fig. 1).
Discussion
Two rather surprising observations were noted
as a result of the autopsy data. First, platinum
was present in detectable levels in one or more
tissues in almost halfofthe individuals studied. It
was thought that platinum would be an entirely
new environmental contaminant, exposure to
which had previously been occupational (mining,
refining) only (1). Second, subcutaneous fat as a
"target" site for platinum deposition was unex-
pected. Previous work with animals identified
kidney, liver, and spleen as chief deposition sites
for platinum (4,5). Perhaps level of exposure is
important. The presence of platinum in subcutan-
eous fat raises the question of transport, since
most platinum compounds are lipid-insoluble.
Conversion to lipid-soluble compounds through
methylation of platinum compounds is one possi-
ble explanation ofpotential significance.
Recent work by Taylor (6) has shown that at
least two platinum compounds, platinic sulfate
and potassium hexachloroplatinate, can be meth-
ylated via the same methylcobalamin (Me-B12)
reaction as involved in-methylation of mercury.
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133Table 4. Distribution oftissue samples showingplatinum.
No. samples
showing Pt °/ ofsam-
No. samples (>detection ples in which
Tissue sample type analyzed limit) Pt detected
Subcutaneous fat a 74 10 13.51
Kidney 91 11 12.09
Pancreas 84 10 11.90
Liver 90 10 11.11
Brain 9 1 11.11
Gonad 53 5 9.43
Adrenals 60 3 5.00
Muscle (psoas) 97 4 4.12
Aorta (descending) 92 3 3.26
Heart (left ventricle) 82 2 2.44
Spleen 52 1 2.00
Prostate or uterus 63 1 1.59
Thyroid 73 1 1.37
Lung 95 0 0
Vertebrae (lumbar) 94 0 0
Fifthrib 97 0 0
Femur 57 0 0
Clavicle 30 0 0
Scalp hair 9 0 0
Pubic hair 1 0 0
Total 1313 62 5.0
aTo determine whether this surprisingly high number of
elevated levels might be the result of larger samples supplied
in one batch (single hospital source), the average subcutaneous
fat sample weight (MAg of wet tissue) was computed for each
batch. The batch in which seven of the ten levels were found
averaged 20.78 Ag per fat sample; the average weights for the
other four batches were 20.97, 14.44, 19.80, and 32.81 Ag,
respectively. Size of sample available for analysis may there-
fore be discounted as afactor.
Whether or not this reaction takes place in the
normal environment or in the human body has not
been established. Since it has been established
that methylation can occur under laboratory con-
ditions, EPA is planning a research program to
determine biological activity of the methylated
platinum product of this methylcobalamin reac-
tion.
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